Leveraging dynamic multiomics and AI to detect, stratify, and predict disease progression months before symptoms emerge.
These three diseases affect over a billion people and often go undetected until it’s too late. Our AI-driven approach enables early prediction—before symptoms ever appear.
AI Tasks
Predict
Anticipate disease risks—such as heart failure, kidney decline, or lung cancer—up to 12 months in advance using adaptive multiomic models.
Detect & Stratify
Non-invasively identify early or hidden disease states (e.g. arterial narrowing, COPD) and assess severity using cfDNA, evRNA, and immune profiling.
Personalize
Generate individualized risk profiles and insights based on molecular subtypes, symptoms, and treatment response—enabling precise, real-time interventions.
Coronary Artery Disease (CAD) & Heart Failure
Cardiovascular disease affects 400M+ people, with 20M at risk of heart failure. Traditional diagnostics are invasive and miss early warning signs—our AI offers a better way.
Predicting Heart Failure Before It Strikes
AI for Early Heart Failure Detection
Affecting 400M+ people worldwide—and often missed until it’s too late.
Heart disease remains the world’s most common and deadly chronic illness. Our AI-powered approach identifies high-risk individuals months before symptoms emerge, enabling earlier and more effective interventions.
Problem + Stats
The Challenge
- 400M+ live with CAD
- 20M expected to develop heart failure
- Diagnosis often requires invasive angiography
The Opportunity
- Detect arterial stenosis non-invasively
- Predict heart failure risk 12 months in advance
- Support early clinical intervention with AI
Catching Kidney Decline Before It Begins
Coronary Artery Disease (CAD) & Heart Failure
Cardiovascular disease affects 400M+ people, with 20M at risk of heart failure. Traditional diagnostics are invasive and miss early warning signs—our AI offers a better way.
AI-Powered Insight Into Hidden Renal Risk
Impacting over 540M people with diabetes—and often unnoticed until permanent damage is done.
Kidney failure is a major complication of type 2 diabetes—often with no warning signs. Our AI detects subtle changes before lab tests, enabling earlier, more targeted care.
Problem + Stats
The Challenge
- 540M+ people with T2D globally
- 20M expected to develop kidney failure
- Early-stage kidney decline often goes unnoticed
- Standard tests lack precision for T2D subtypes
The Opportunity
- Stratify patients into meaningful subtypes
- Detect molecular signs of renal decline early
- Identify biomarkers linked to chronic pain and medication use
- Predict kidney failure within a 12-month window
Coronary Artery Disease (CAD) & Heart Failure
Cardiovascular disease affects 400M+ people, with 20M at risk of heart failure. Traditional diagnostics are invasive and miss early warning signs—our AI offers a better way.
Detecting Lung Cancer Before It Surfaces
AI for Early Lung Cancer and COPD Detection
390 million affected—yet 65% remain unaware of their condition.
COPD and lung cancer often progress silently. Our AI models identify disease risk up to 12 months in advance, enabling early action in patients who would otherwise go unnoticed.
Problem + Stats
The Challenge
- 390M+ people live with COPD
- 25M expected to develop lung cancer
- 65% of COPD cases remain undiagnosed
- Early-stage lung cancer often lacks symptoms
The Opportunity
- Early-stage lung cancer often lacks symptoms
- Grade COPD severity non-invasively
- Predict lung cancer development within 12 months
- Enable early screening and risk-based monitoring
There is a general tendency for people to ignore heart failure symptoms and attribute them to just getting older.
— Dr. Mandeep R. Mehra
Kidney disease often goes unnoticed until it reaches advanced stages, which is why it’s often called the “silent killer.”
— National Kidney Foundation